Core Viewpoint - Zealand Pharma A/S has announced the implementation of long-term incentive programs for 2025 aimed at aligning the interests of its Board of Directors, Corporate Management, and employees with those of shareholders, while also attracting and retaining top talent [1][2]. Long-term Incentive Program - The long-term incentive program includes the granting of restricted share units (RSUs) and performance share units (PSUs) to various stakeholders within the company [2][10]. - The program is designed to align with selected European and U.S. biotech peers and to drive long-term performance [2]. Board of Directors - A total of 29,169 RSUs have been awarded to Zealand Pharma's Board of Directors, with vesting occurring annually in equal tranches over three years [10][5]. - The maximum number of RSUs granted to any Board member is capped at 8,000, with specific monetary limits based on their roles [6]. - Board members are required to hold RSUs equivalent to 200% of their annual grant value within two years of their election [7]. Corporate Management - Zealand Pharma's Corporate Management has been awarded 96,788 PSUs and 96,788 RSUs, with an estimated fair market value of DKK 82.2 million [10][13]. - The PSUs vest based on predefined performance targets, with potential vesting ranging from 0% to 150% after three years [11][12]. - RSUs for Corporate Management will vest annually in equal tranches over three years [12]. Employee Grants - US employees have been awarded 18,502 RSUs, while employees in Denmark have received 128,519 RSUs, with respective estimated fair market values of DKK 7.9 million and DKK 54.6 million [10][17][20]. - RSUs for US employees and employees in Denmark will vest annually in equal tranches over three years, with conditions tied to continued employment [16][19]. Company Overview - Zealand Pharma A/S is a biotechnology company focused on the discovery and development of peptide-based medicines, with over 10 drug candidates in clinical development [22]. - The company has established partnerships with several major pharmaceutical companies and has a presence in both Denmark and the United States [22][23].

Core Viewpoint - BW Offshore Limited has approved new awards under its Long-Term Incentive Programme (LTIP) for 2025, which includes Share Options and Restricted Share Units (RSUs) to align employee interests with those of shareholders [1][2]. Summary by Sections Long-Term Incentive Programme (LTIP) - The LTIP for 2025 includes a total of 800,000 options, each granting the right to acquire one BW Offshore share [2]. - The programme is discretionary, with annual invitations extended to participants [1]. Option Details - The strike price for the options is set at NOK 32.19, calculated based on the volume weighted average share price from five trading days prior to the grant date, plus a 15.76% premium [3]. - Options have a vesting period of three years, followed by a three-year exercise period, and will expire six years after the award date [3]. Conditions and Awards - Options are non-tradable and contingent upon the holder's employment status with the company [4]. - In 2025, 92,400 RSUs were awarded to 18 employees, which will be settled in shares after a three-year vesting period [4]. Key Executives and Awards - Chief Executive Officer Marco Beenen received 300,000 options, while other executives received varying amounts, including: - Chief Financial Officer Ståle Andreassen: 100,000 options - Chief Commercial Officer Mona Rajoo: 100,000 options - Chief Technical Officer Mike McAreavey: 100,000 options - Chief Strategy Officer Anders S. Platou: 100,000 options - General Counsel Ming Yen Yip: 100,000 options [4]. Company Overview - BW Offshore specializes in innovative floating production solutions and operates a fleet of three Floating Production Storage and Offloading (FPSO) units, with aspirations for growth [5]. - The company has approximately 1,100 employees and is publicly listed on the Oslo Stock Exchange [5].